These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 26639968)
1. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam. Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968 [TBL] [Abstract][Full Text] [Related]
2. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. de Groot M; Aronica E; Heimans JJ; Reijneveld JC Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655 [TBL] [Abstract][Full Text] [Related]
3. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Sanchez PE; Zhu L; Verret L; Vossel KA; Orr AG; Cirrito JR; Devidze N; Ho K; Yu GQ; Palop JJ; Mucke L Proc Natl Acad Sci U S A; 2012 Oct; 109(42):E2895-903. PubMed ID: 22869752 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer's Disease. Stockburger C; Eckert S; Eckert GP; Friedland K; Müller WE J Alzheimers Dis; 2018; 64(s1):S455-S467. PubMed ID: 29504539 [TBL] [Abstract][Full Text] [Related]
5. Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam. Stockburger C; Kurz C; Koch KA; Eckert SH; Leuner K; Müller WE Biochem Soc Trans; 2013 Oct; 41(5):1331-4. PubMed ID: 24059528 [TBL] [Abstract][Full Text] [Related]
6. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. Devi L; Ohno M Neurobiol Learn Mem; 2013 May; 102():7-11. PubMed ID: 23416036 [TBL] [Abstract][Full Text] [Related]
7. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Gillard M; Chatelain P; Fuks B Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440 [TBL] [Abstract][Full Text] [Related]
8. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715 [TBL] [Abstract][Full Text] [Related]
9. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. Dragicevic N; Mamcarz M; Zhu Y; Buzzeo R; Tan J; Arendash GW; Bradshaw PC J Alzheimers Dis; 2010; 20 Suppl 2():S535-50. PubMed ID: 20463404 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function. Stockburger C; Miano D; Pallas T; Friedland K; Müller WE Neural Plast; 2016; 2016():8075903. PubMed ID: 27747106 [TBL] [Abstract][Full Text] [Related]
11. Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease. Xiao R Curr Top Med Chem; 2016; 16(5):565-73. PubMed ID: 26268327 [TBL] [Abstract][Full Text] [Related]
12. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974 [TBL] [Abstract][Full Text] [Related]
13. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. Reddy PH; Manczak M; Mao P; Calkins MJ; Reddy AP; Shirendeb U J Alzheimers Dis; 2010; 20 Suppl 2(Suppl 2):S499-512. PubMed ID: 20413847 [TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Dysfunction Triggers Synaptic Deficits via Activation of p38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells. Yu Q; Du F; Douglas JT; Yu H; Yan SS; Yan SF J Alzheimers Dis; 2017; 59(1):223-239. PubMed ID: 28598851 [TBL] [Abstract][Full Text] [Related]
15. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. Serajee FJ; Huq AM Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053 [TBL] [Abstract][Full Text] [Related]
16. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease. Reddy PH; Manczak M; Yin X; Grady MC; Mitchell A; Kandimalla R; Kuruva CS J Investig Med; 2016 Dec; 64(8):1220-1234. PubMed ID: 27521081 [TBL] [Abstract][Full Text] [Related]
17. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Calkins MJ; Manczak M; Mao P; Shirendeb U; Reddy PH Hum Mol Genet; 2011 Dec; 20(23):4515-29. PubMed ID: 21873260 [TBL] [Abstract][Full Text] [Related]
18. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease. Hall AM; Throesch BT; Buckingham SC; Markwardt SJ; Peng Y; Wang Q; Hoffman DA; Roberson ED J Neurosci; 2015 Apr; 35(15):6221-30. PubMed ID: 25878292 [TBL] [Abstract][Full Text] [Related]
19. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214 [TBL] [Abstract][Full Text] [Related]
20. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. Madeo M; Kovács AD; Pearce DA J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]